Drugs / MMRVNS
last change May 2026 re-read 3 minutes ago

MMRVNS

Vaccine

Developed for
measles
Investigated by
GlaxoSmithKline

Trials 1

20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07406360 May 2026 → Feb 2028 expected measles GlaxoSmithKline Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MMRVNS ClinicalTrials.gov intervention name — accepted as the source's own label NCT07406360 ↗
Modality Vaccine “Investigational measles, mumps, rubella and varicella vaccine” NCT07406360 ↗
Route Intramuscular “One dose of MMRVNS administered intramuscularly.” NCT07406360 ↗